We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's (AZN) Coronavirus Vaccine Gets EUA in Japan
Read MoreHide Full Article
AstraZeneca PLC (AZN - Free Report) announced that the Japanese Ministry of Health, Labour and Welfare has granted a special approval for emergency use of its COVID-19 vaccine, Vaxzevria, for active immunization of individuals aged 18 years and above in the country.
The emergency use approval was based on positive efficacy and safety data from a phase III Oxford University-led clinical study program held in the United Kingdom, Brazil and South Africa, as well as a phase I/II study in Japan.
The recommended use of the vaccine is two 0.5 mL doses administered intramuscularly, given four to 12 weeks apart. A gap of more than eight weeks is being considered preferable to maximize the vaccine's efficacy.
Notably, the first doses of the vaccine are expected to be available in the coming weeks in Japan.
Shares of AstraZeneca have rallied 14.8% so far this year compared with industry’s increase of 7.4%.
Notably, AstraZeneca’s COVID-19 vaccine is approved for emergency/condition use in more than 80 countries, but not in the United States. The company plans to submit a regulatory application seeking emergency use authorization (“EUA”) for its COVID-19 vaccine in the United States in a few weeks.
During the first quarter of 2021, AstraZeneca announced data from primary analysis of U.S. phase III study of its COVID-19 vaccine, which showed vaccine efficacy of 76% at preventing symptomatic COVID-19, consistent with previously reported interim data. Moreover, vaccine efficacy was 85% in adults 65 years and older and the vaccine was 100% effective in preventing severe or critical disease and hospitalization.
In the first quarter of 2021, AstraZeneca’s COVID-19 vaccine added $275 million to revenues from delivery of 68 million doses in several countries.
Other approved coronavirus vaccines for emergency use include Pfizer (PFE - Free Report) /BioNTech’s BNT162b, Moderna’s (MRNA - Free Report) mRNA-1273 and J&J’s (JNJ - Free Report) single-shot coronavirus vaccine.
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Image: Bigstock
AstraZeneca's (AZN) Coronavirus Vaccine Gets EUA in Japan
AstraZeneca PLC (AZN - Free Report) announced that the Japanese Ministry of Health, Labour and Welfare has granted a special approval for emergency use of its COVID-19 vaccine, Vaxzevria, for active immunization of individuals aged 18 years and above in the country.
The emergency use approval was based on positive efficacy and safety data from a phase III Oxford University-led clinical study program held in the United Kingdom, Brazil and South Africa, as well as a phase I/II study in Japan.
The recommended use of the vaccine is two 0.5 mL doses administered intramuscularly, given four to 12 weeks apart. A gap of more than eight weeks is being considered preferable to maximize the vaccine's efficacy.
Notably, the first doses of the vaccine are expected to be available in the coming weeks in Japan.
Shares of AstraZeneca have rallied 14.8% so far this year compared with industry’s increase of 7.4%.
Notably, AstraZeneca’s COVID-19 vaccine is approved for emergency/condition use in more than 80 countries, but not in the United States. The company plans to submit a regulatory application seeking emergency use authorization (“EUA”) for its COVID-19 vaccine in the United States in a few weeks.
During the first quarter of 2021, AstraZeneca announced data from primary analysis of U.S. phase III study of its COVID-19 vaccine, which showed vaccine efficacy of 76% at preventing symptomatic COVID-19, consistent with previously reported interim data. Moreover, vaccine efficacy was 85% in adults 65 years and older and the vaccine was 100% effective in preventing severe or critical disease and hospitalization.
In the first quarter of 2021, AstraZeneca’s COVID-19 vaccine added $275 million to revenues from delivery of 68 million doses in several countries.
Other approved coronavirus vaccines for emergency use include Pfizer (PFE - Free Report) /BioNTech’s BNT162b, Moderna’s (MRNA - Free Report) mRNA-1273 and J&J’s (JNJ - Free Report) single-shot coronavirus vaccine.
Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>